Axsome Therapeutics(US:AXSM)2026-03-09 21:22Axsome Therapeutics Conference Call Summary Company Overview - Company: Axsome Therapeutics (NasdaqGM:AXSM) - Date: March 09, 2026 - Key Speakers: Mark Jacobson (COO), Nick Pizzie (CFO) Key Points Auvelity Performance and Strategy - Auvelity annualized revenue at the end of 2025 was just over $600 million, marking its third full year since launch in 2022, outperforming peers in the market [6][7] - The sales force expanded from 160 to 300 representatives in 2025, with plans to double to 600 in 2026, focusing on Major Depressive Disorder (MDD) and the anticipated approval for Agitation in Alzheimer’s Disease (ADA) [7][8] - Peak sales projections for Auvelity are estimated between $1 billion to $3 billion for MDD and $1.5 billion to $3 billion for ADA [7] - Market access has improved to 86% coverage of total lives, with 100% coverage in the government channel and 78% on the commercial side [21][22] - Direct-to-consumer (DTC) advertising began in September 2025, with adjustments made based on learnings from the initial campaign [18][19] Clinical and Market Dynamics - Auvelity's clinical profile shows a distinct safety and tolerability profile, with over 50% of prescriptions now coming from first and second-line treatments [8][9] - The product is gaining traction in primary care, with about 33% of scripts originating from this sector [9] - The company is reallocating resources from DTC to expand the sales team, anticipating that this will enhance the effectiveness of future DTC campaigns [18][19] Upcoming Indications and Trials - The PDUFA date for ADA is set for April 30, 2026, with preparations underway for potential FDA approval [23][24] - Axsome is also exploring a smoking cessation indication for Auvelity, with clinical operations set to begin soon [30][32] Symbravo Launch - Symbravo is performing well in the migraine space, with a focus on later-line treatment due to payer management [36][37] - The sales force for Symbravo is currently 100 reps, with a strategy to refine the launch based on early utilization data [40][41] - Market access for Symbravo is around 50% covered lives, with recent contracts signed to improve access [45] Sunosi Growth - Sunosi has seen a 40% year-over-year growth, supported by a dedicated team of 70 reps [55][57] - The company is optimistic about further accelerating revenue through four indications currently in development [57] AXS-14 and AXS-17 Developments - AXS-14 (esreboxetine) is targeting the fibromyalgia market, with a new phase 3 trial launched after a previous Refuse to File due to trial design issues [87][89] - AXS-17 is a new product for epilepsy, with plans for phase 2 enabling work in 2026, focusing on unmet needs in the epilepsy space [106][107] AXS-12 Submission - AXS-12, targeting narcolepsy with a focus on cataplexy, is at the NDA stage, with submission expected soon [121] Additional Insights - The company is strategically focusing on expanding its pipeline and market presence while addressing regulatory feedback to enhance product approvals [89][90] - There is a strong emphasis on understanding market dynamics and patient needs to drive product utilization and acceptance [41][57]